PE20120495A1 - 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas - Google Patents

3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas

Info

Publication number
PE20120495A1
PE20120495A1 PE2011001933A PE2011001933A PE20120495A1 PE 20120495 A1 PE20120495 A1 PE 20120495A1 PE 2011001933 A PE2011001933 A PE 2011001933A PE 2011001933 A PE2011001933 A PE 2011001933A PE 20120495 A1 PE20120495 A1 PE 20120495A1
Authority
PE
Peru
Prior art keywords
cyclopentilamino
difluor
propanoate
intermediary
preparation
Prior art date
Application number
PE2011001933A
Other languages
English (en)
Spanish (es)
Inventor
Shaoqing Chen
Peter Michael Wovkulich
Kin-Chun Thomas Luk
Xin-Jie Chu
Jianping Cai
Kang Le
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120495(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20120495A1 publication Critical patent/PE20120495A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2011001933A 2007-03-22 2008-03-19 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas PE20120495A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
PE20120495A1 true PE20120495A1 (es) 2012-05-12

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001933A PE20120495A1 (es) 2007-03-22 2008-03-19 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas

Country Status (23)

Country Link
US (1) US7517873B2 (OSRAM)
EP (1) EP2139892B1 (OSRAM)
JP (1) JP5087640B2 (OSRAM)
KR (1) KR101157848B1 (OSRAM)
CN (2) CN101636399B (OSRAM)
AR (1) AR065794A1 (OSRAM)
AT (1) ATE524472T1 (OSRAM)
AU (1) AU2008228303B2 (OSRAM)
BR (1) BRPI0809088A2 (OSRAM)
CA (1) CA2680757A1 (OSRAM)
CL (1) CL2008000785A1 (OSRAM)
CY (1) CY1112102T1 (OSRAM)
DK (1) DK2139892T3 (OSRAM)
ES (1) ES2371832T3 (OSRAM)
HR (1) HRP20110807T1 (OSRAM)
IL (1) IL200617A (OSRAM)
MX (1) MX2009010034A (OSRAM)
PE (1) PE20120495A1 (OSRAM)
PL (1) PL2139892T3 (OSRAM)
PT (1) PT2139892E (OSRAM)
SI (1) SI2139892T1 (OSRAM)
TW (1) TWI363629B (OSRAM)
WO (1) WO2008113711A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695753A1 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
MX2010003249A (es) * 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas símil polo.
CN101878216B (zh) 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9676792B2 (en) * 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EA201790024A1 (ru) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
CN109311901A (zh) * 2016-04-07 2019-02-05 达纳-法伯癌症研究所有限公司 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法
AU2020356484A1 (en) * 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
WO2023017442A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK3792002A3 (en) 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Kinase inhibitors as therapeutic agents
HRP20040213A2 (en) * 2001-09-04 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
DE602007008837D1 (de) * 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ES2371832T3 (es) 2012-01-10
CN102746175B (zh) 2014-01-15
DK2139892T3 (da) 2011-12-12
US7517873B2 (en) 2009-04-14
JP5087640B2 (ja) 2012-12-05
HK1139936A1 (en) 2010-09-30
KR101157848B1 (ko) 2012-07-11
HRP20110807T1 (hr) 2011-12-31
TW200843781A (en) 2008-11-16
ATE524472T1 (de) 2011-09-15
IL200617A0 (en) 2010-05-17
MX2009010034A (es) 2009-10-12
PL2139892T3 (pl) 2012-03-30
EP2139892B1 (en) 2011-09-14
PT2139892E (pt) 2011-11-21
JP2010521514A (ja) 2010-06-24
AU2008228303B2 (en) 2012-04-19
CL2008000785A1 (es) 2009-03-27
SI2139892T1 (sl) 2011-12-30
EP2139892A1 (en) 2010-01-06
CA2680757A1 (en) 2008-09-25
KR20090119913A (ko) 2009-11-20
TWI363629B (en) 2012-05-11
CY1112102T1 (el) 2015-11-04
CN101636399A (zh) 2010-01-27
CN102746175A (zh) 2012-10-24
US20080234255A1 (en) 2008-09-25
AR065794A1 (es) 2009-07-01
BRPI0809088A2 (pt) 2014-09-09
AU2008228303A1 (en) 2008-09-25
CN101636399B (zh) 2012-04-18
WO2008113711A1 (en) 2008-09-25
IL200617A (en) 2014-02-27

Similar Documents

Publication Publication Date Title
PE20120495A1 (es) 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
SV2011003853A (es) Compuestos organicos
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CR20120295A (es) Triazolopiridinas
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
CR20130349A (es) COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
CR20120348A (es) Nuevos compuestos tricíclicos
CR20140132A (es) Derivados de pirrolopirimidina y purina
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
SV2010003472A (es) Compuestos de pirazol
CR20120121A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
EA201100503A1 (ru) Глюкозидные производные и их применения
ECSP11010889A (es) INHIBIDORES DE cMET
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed